Early COPERNICUS results show subcutaneous amivantamab and proactive VTE and skin prophylaxis sharply reduce reactions, helping NSCLC patients stay on therapy.
Amanda Edmond, PA-C
Advertisement
Articles by Amanda Edmond, PA-C
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Oncology Nursing News
1
Nurse-Led Strategies for Vitamin D in Cancer Care
2
Cancer Surgery Waiting Times Rising: What Oncology Nurses Need to Know
3
How An Adaptive Weight-Loss Strategy Benefits Breast Cancer Survivors
4
Using Biomarker Testing to Personalize Metastatic Triple-Negative Breast Cancer Care
5